Gamal Akabani

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

George Sgouros, John C. Roeske, Michael R. McDevitt et al. · Journal of Nuclear Medicine · 2010 · 533 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Clinical Experience with α-Particle–Emitting ²¹¹At: Treatment of Recurrent Brain Tumor Patients with ²¹¹At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Michael R. Zalutsky, David A. Reardon, Gamal Akabani et al. · Journal of Nuclear Medicine · 2007 · 396 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Migration of human dendritic cells after injection in patients with metastatic malignancies.

Michael A. Morse, Rob Coleman, Gamal Akabani et al. · PubMed · 1999 · 354 citations

Medicine, Immunology, Oncology +17

Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

John H. Sampson, Gamal Akabani, Gary E. Archer et al. · Journal of Neuro-Oncology · 2003 · 239 citations

Medicine, Neuroscience, Oncology +8

Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

David A. Reardon, Gamal Akabani, R. Edward Coleman et al. · Journal of Clinical Oncology · 2005 · 200 citations

Medicine, Nuclear Medicine, Oncology +17